The cardiac persistent sodium current: an appealing therapeutic target?

Saint, D A

Saint, D A.

Affiliation

Saint DA; School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia. david.saint@Adelaide.edu.au

Br J Pharmacol ; 153(6): 1133-42, 2008 Mar.

Article in En | MEDLINE | ID: mdl-18071303

Subject(s)

Myocardial Ischemia/drug therapy; Sodium Channel Blockers/pharmacology; Sodium Channels/drug effects; Acetanilides/adverse effects; Acetanilides/pharmacology; Animals; Controlled Clinical Trials as Topic; Drug Delivery Systems; Drug Therapy, Combination; Electrophysiology; Enzyme Inhibitors/adverse effects; Enzyme Inhibitors/pharmacology; Humans; Myocardial Ischemia/physiopathology; Piperazines/adverse effects; Piperazines/pharmacology; Potassium Channel Blockers/pharmacology; Ranolazine; Sodium Channel Blockers/adverse effects; Sodium Channels/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sodium Channels / Myocardial Ischemia / Sodium Channel Blockers Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Br J Pharmacol Year: 2008 Type: Article Affiliation country: Australia

Fulltext

XML

PubMed Links

Search on Google